Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (186)

« Back to Publications

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.

Hamilton DO. et al, (2026), PLoS Negl Trop Dis, 20

Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Mamede I. et al, (2026), Front Immunol, 17

Persistent pneumococcal colonisation in antiretroviral-treated HIV infection is associated with nasal inflammation.

Phiri JA. et al, (2025), Nat Commun, 17

Systematic review of antimycobacterial therapy for Bacille Calmette-Guérin infection in hosts without significant immunocompromise.

Carter EC. et al, (2025), Int J Infect Dis, 161

Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

Gbesemete D. et al, (2025), Lancet Microbe, 6

Controlled human infection model (CHIM) inoculum production in Malawi using principles of good manufacturing practice

Chikaonda T. et al, (2025), Vaccine X, 27

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).

Macedo BRD. et al, (2025), BMJ Open, 15

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies

Cheliotis KS. et al, (2025)

Machine Learning-Driven Identification of Serotype-Independent Pneumococcal Vaccine Candidates using samples from Human Infection Challenge Studies

Cheliotis KS. et al, (2025)

High Propensity for Multidrug-Resistant Pneumococcal Shedding Among Adults Living With HIV on Stable Antiretroviral Therapy in Malawi.

Sibale LL. et al, (2025), Open Forum Infect Dis, 12

Load More

1
2
3
4
5
6
7
...
»